Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Lung Cancer | Research article

LncRNA LINC01116 sponges miR-93-5p to promote cell invasion and migration in small cell lung cancer

Authors: Wenzhou Liu, Feihai Liang, Guangyu Yang, Lei Xian

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

LINC01116 is a recently identified oncogenic lncRNA in glioma. Differential expression analysis using the public gene expression analysis tool GEPIA revealed the upregulation of LINC01116 in lung cancer. We studied the functions of LINC01116 in small cell lung cancer (SCLC).

Methods

The expression of LINC01116 in several types of cancer tissue and the paired non-tumor tissues was evaluated by GEPIA. The effects of the overexpression of LINC01116 and miR-93-5p on the expression of STAT3 were evaluated. The effects of the overexpression of LINC01116, miR-93-5p and STAT3 on SHP-77 cell behaviors were evaluated by Transwell assays.

Results

LINC01116 was highly expressed in SCLC and predicted poor survival. In SCLC tissues, the expression of LINC01116 was positively correlated with STAT3. Bioinformatics analysis revealed that miR-93-5p may target LINC01116. Overexpression of LINC01116 increased STAT3 but did not affect the expression of miR-93-5p. Transwell assay showed that LINC01116 and STAT3 increased cell invasion and migration rates. MiR-93-5p played an suppressed cell behaviors and suppressed the role of LINC01116.

Conclusion

Therefore, LINC01116 might upregulate STA3 by sponging miR-93-5p, thereby promoting cell invasion and migration in SCLC.
Literature
1.
go back to reference Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725.CrossRef Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725.CrossRef
2.
go back to reference Pirie K, Peto R, Green J, Reeves GK, Beral V, Collaborators MWS. Lung cancer in never smokers in the UK Million Women Study. Int J Cancer. 2016;139(2):347–54.CrossRef Pirie K, Peto R, Green J, Reeves GK, Beral V, Collaborators MWS. Lung cancer in never smokers in the UK Million Women Study. Int J Cancer. 2016;139(2):347–54.CrossRef
3.
go back to reference Gazdar AF, Minna JD. Small cell lung cancers made from scratch. New York: Rockefeller University Press; 2019.CrossRef Gazdar AF, Minna JD. Small cell lung cancers made from scratch. New York: Rockefeller University Press; 2019.CrossRef
4.
go back to reference Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23.CrossRef Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23.CrossRef
5.
go back to reference Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39.PubMedPubMedCentral Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39.PubMedPubMedCentral
6.
go back to reference Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28(2 Suppl 4):3–13.CrossRef Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28(2 Suppl 4):3–13.CrossRef
7.
go back to reference Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Kawakami Y. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 2005;12(1):95.CrossRef Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Kawakami Y. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 2005;12(1):95.CrossRef
8.
go back to reference Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798.CrossRef Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798.CrossRef
9.
go back to reference Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. BioMed Res Int. 2013;2013:421821.CrossRef Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. BioMed Res Int. 2013;2013:421821.CrossRef
10.
go back to reference Xiang Y, Liao X-H, Yu C-X, Yao A, Qin H, Li JP, Gu CJ. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res. 2017;357(1):135–44.CrossRef Xiang Y, Liao X-H, Yu C-X, Yao A, Qin H, Li JP, Gu CJ. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res. 2017;357(1):135–44.CrossRef
11.
go back to reference Ye J, Zhu J, Chen H, Qian J, Zhang L, Wan Z, Luo C. A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int J Cancer. 2020;146(1):248–61.CrossRef Ye J, Zhu J, Chen H, Qian J, Zhang L, Wan Z, Luo C. A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int J Cancer. 2020;146(1):248–61.CrossRef
12.
go back to reference Fang Y, Huang Z, Li H, Tan W, Zhang Q, Wang L, Wu J. LINC01116 promotes the progression of epithelial ovarian cancer via regulating cell apoptosis. Eur Rev Med Pharmacol Sci. 2018;22(16):5127–33.PubMed Fang Y, Huang Z, Li H, Tan W, Zhang Q, Wang L, Wu J. LINC01116 promotes the progression of epithelial ovarian cancer via regulating cell apoptosis. Eur Rev Med Pharmacol Sci. 2018;22(16):5127–33.PubMed
13.
go back to reference Hu H, Chen Q, Ding S. LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):1987–93.PubMed Hu H, Chen Q, Ding S. LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):1987–93.PubMed
14.
go back to reference Li L, Zhao J, Huang S, Wang Y, Zhu L, Cao Y, Deng J. MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. Gene. 2018;641:240–7.CrossRef Li L, Zhao J, Huang S, Wang Y, Zhu L, Cao Y, Deng J. MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. Gene. 2018;641:240–7.CrossRef
15.
go back to reference Shyamasundar S, Lim JP, Bay BH. miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1. Int J Oncol. 2016;49(6):2629–36.CrossRef Shyamasundar S, Lim JP, Bay BH. miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1. Int J Oncol. 2016;49(6):2629–36.CrossRef
16.
go back to reference Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang JF. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513.CrossRef Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang JF. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513.CrossRef
17.
go back to reference Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genetics. 2016;17(5):272–83.CrossRef Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genetics. 2016;17(5):272–83.CrossRef
18.
go back to reference Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA–lncRNA interactions. Methods Mol Biol. 2016;1402:271–86.PubMed Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA–lncRNA interactions. Methods Mol Biol. 2016;1402:271–86.PubMed
Metadata
Title
LncRNA LINC01116 sponges miR-93-5p to promote cell invasion and migration in small cell lung cancer
Authors
Wenzhou Liu
Feihai Liang
Guangyu Yang
Lei Xian
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01369-3

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.